Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Scott Pain"'
Autor:
Ingo Fietze, Alberto Gimona, Yves Dauvilliers, James Khoo, Gary Zammit, David Mayleben, Scott Pain, Dalma Seboek Kinter
Publikováno v:
BMJ Open Respiratory Research, Vol 10, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e1fed8166bc040faa4c81d53be39d9df
Autor:
Ingo, Fietze, Claudio L A, Bassetti, David W, Mayleben, Scott, Pain, Dalma, Seboek Kinter, William V, McCall
Publikováno v:
Drugsaging. 39(10)
The dual orexin receptor antagonist daridorexant, studied in two phase III trials, dose-dependently improved objective and subjective sleep variables and daytime functioning in adults with insomnia. Because treatment of insomnia in older adults is ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a9dc4779b03f0a0f2f7ce83653ef15c2
https://pubmed.ncbi.nlm.nih.gov/36098936
https://pubmed.ncbi.nlm.nih.gov/36098936
Autor:
Yves Dauvilliers, Gary Zammit, Scott Pain, David Mayleben, Dalma Seboek Kinter, Ingo Fietze, Jan Hedner
Publikováno v:
Annals of Neurology. 88:647-651
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::054df73ca5e4c6120cc370a473ad975e
https://doi.org/10.1002/ana.25801
https://doi.org/10.1002/ana.25801
Autor:
Ingo Fietze, Claudio Bassetti, David Mayleben, Alberto Gimona, Scott Pain, William McCall, Dalma Seboek Kinter
Publikováno v:
The American Journal of Geriatric Psychiatry. 30:S69-S70
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7e64cb43c70ed97ad39dc9b171025c4d
https://doi.org/10.1016/j.jagp.2022.01.064
https://doi.org/10.1016/j.jagp.2022.01.064
Autor:
Dalma Seboek Kinter, Yves Dauvilliers, Ingo Fietze, David Mayleben, Alberto Gimona, Scott Pain, Gary Zammit
Publikováno v:
Sleep. 44:A137-A138
Introduction Daridorexant, a new dual orexin receptor antagonist, improved sleep parameters and daytime functioning in two pivotal Phase 3 trials in patients with insomnia (Trial-1, NCT03545191; Trial-2, NCT03575104); polysomnography data were collec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::deaab266dad4cf9a8185cb1a3be6a76f
https://doi.org/10.1093/sleep/zsab072.343
https://doi.org/10.1093/sleep/zsab072.343
Autor:
Ingo Fietze, Claudio L. Bassetti, David Mayleben, Scott Pain, Alberto Gimona, Dalma Seboek Kinter
Publikováno v:
Sleep. 44:A138-A139
Introduction Insomnia affects elderly more than younger adults, and comorbidities more prevalent in elderly populations can add to symptom burden and reduce therapeutic options. Drugs that improve insomnia symptoms with limited safety risks are neede
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b734a987e8e6bac3aa0e04d8b57e9d99
https://doi.org/10.1093/sleep/zsab072.346
https://doi.org/10.1093/sleep/zsab072.346
Autor:
D Seboek Kinter, Gary Zammit, Thomas Roth, Hermann, Damien Leger, Scott Pain, Claudio L. Bassetti
Publikováno v:
Sleep. 43:A199-A200
Introduction Daridorexant, a potent and selective orally administered dual orexin receptor antagonist (DORA), has shown dose-dependent efficacy and is well tolerated with minimal residual next-morning effects in two phase 2 studies in adult and elder
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::364029672e74411390055bcbe068fff4
https://doi.org/10.1093/sleep/zsaa056.518
https://doi.org/10.1093/sleep/zsaa056.518
Publikováno v:
Neurology. 94(21)
ObjectiveTo assess the dose-response of daridorexant, a new dual orexin receptor antagonist, on wake after sleep onset (WASO).MethodsElderly (≥65 years) participants (n = 58) with insomnia were randomly allocated (Latin square design) to receive 5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37ca5bbb652f92d401b16e4b1b3b617
https://pubmed.ncbi.nlm.nih.gov/32341187
https://pubmed.ncbi.nlm.nih.gov/32341187
Publikováno v:
Sleep. 44:A139-A139
Introduction Abrupt discontinuation of sleep medications in patients with insomnia often causes withdrawal symptoms and rebound insomnia. In a Phase 3 program evaluating efficacy and safety of daridorexant on sleep and daytime functioning in patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ea3938c1cd831e7a31c52a09be89c43
https://doi.org/10.1093/sleep/zsab072.347
https://doi.org/10.1093/sleep/zsab072.347
Publikováno v:
Sleep Medicine. 64:S437-S438
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c226bebafba87e13213b71495daf68a
https://doi.org/10.1016/j.sleep.2019.11.1228
https://doi.org/10.1016/j.sleep.2019.11.1228